Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 2, 2006, Pages 256-265

  Agwuh, Kenneth N ^a   MacGowan, Alasdair ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Pharmacodynamics; Pharmacokinetics; Tetracyclines

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BAY 736944; BETA LACTAM ANTIBIOTIC; CHLORTETRACYCLINE; DEMECLOCYCLINE; DIGOXIN; DOXYCYCLINE; GLYCYLCYCLINE DERIVATIVE; LYMECYCLINE; METACYCLINE; MINOCYCLINE; NEW DRUG; OXYTETRACYCLINE; PTK 0796; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROLITETRACYCLINE; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG; WARFARIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; ENTEROBACTER; ESCHERICHIA COLI; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KLEBSIELLA; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PHARMACODYNAMICS; PROTEUS; RELIABILITY; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; SPECTROFLUOROMETRY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE;

HUMANS; TETRACYCLINES;

EID: 33748057491     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl224     Document Type: Review

References (92)

1. Anonymous. Tetracycline (hydrochloride). In: Dollery C, ed. Therapeutic Drugs, 2nd edn. London: Churchill Livingstone, 1999; T66-9.
2. Welling PG, Koch PA, Lav CC et al. Bioavailability of tetracycline and doxycycline in fasted and non-fasted subjects. Antimicrob Agents Chemother 1977; 11: 462-9.
3. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM, White LO, eds. Clinical Antimicrobial Assays. Oxford: Oxford University Press, 1999; 35-44.
4. White LO, Lovering AM. Non-microbiological assays. In: Reeves DS, Wise R, Andrews JM, White LO, eds. Clinical Antimicrobial Assays. Oxford: Oxford University Press, 1999; 45-64.
5. Fabre J, Milek E, Kalpopoulos et al. La Cinetique des tetracyclines chez l'homme. Schweiz med Wschr 1977; 101, 573-8.
6. Chopra I. Tetracyclines. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ, eds. Antibiotic and Chemotherapy: Anti-infective Agents and their Use. London: Churchill Livingstone, 2003; 393-406.
7. Anonymous. Oxytetracycline (dihydrate). In: Dollery C, ed. Therapeutic Drugs, 2nd edn. London: Churchill Livingstone, 1999; O55-9.
8. Anonymous. Demedocycline (hydrochloride). In: Dollery C, ed. Therapeutic Drugs, 2nd edn. London: Churchill Livingstone, 1999; D29-31.
9. Anonymous. Chlortetracycline (hydrochloride). In: Dollery C, ed. Therapeutic Drugs, 2nd edn. London: Churchill Livingstone, 1999; C199-201.
10. Smilack JD. The tetracyclines. Mayo Clinic Proceedings 1999; 74: 729-729.
11. Sjolin-Forsberg G, Hermannson J. Comparative bioavailability of tetracycline and lymecycline. Br J Clin Pharmacol 1984; 18: 529-33.
12. Steigbigel NH, Reed CW, Finland M. Absorption and excretion of five tetracycline analogues in normal young men. Am J Med Sci 1968; 255: 296-312.
13. Kunin C, Dornbush AC, Finland M. Distribution and excretion of four tetracycline analogues in normal young men. J Clin Invest 1966; 38: 1950-9.
14. Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs 1976; 11: 45-54.
15. Klein NC, Cunha BA. Tetracyclines. Med Clin North Am 1995; 79: 789-801.
16. Kunin CM, Rees SB, Merrill JP et al. Persistence of antibiotics in blood of patients with acute renal failure I tetracycline and chlortetracycline. J Clin Invest 1959; 38: 1487-97.
17. Vincon G, Albin J, Paccalin J et al. Elimination des antibiotiques dans la bile. Bordeaux Medical 1979; 12: 795-9.
18. Ylitalo P, Hinkka H, Neuvonen PJ. Effect of exercise on the serum level and urinary excretion of tetracycline, doxycycline and sulphamethizole. European J Clin Pharmacol 1977; 12; 367-73.
19. Anonymous. Doxycycline hyclate. In: Dollery C, ed. Therapeutic Drugs, 2nd edn. Churchill Livingstone, 1999; D229-32.
20. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15: 355-66.
21. Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med 1997; 157: 1421-8.
22. Bergogne-Berezin E, Lambert-Zechousky N. La doxycycline: Quelgues proprietes bacteriologiques et pharmacologiques. Gazette Medicale de Franc 1976; 83: 53-8.
23. Saux MC, Mosser J, Pontagnier H et al. Pharmacokinetic study of doxycycline polyphosphate, hydrochloride and base. Eur J Drug Metab Pharmacokinet 1981; 6: 3-10.
24. Fourtillan JB, Lefebrre MA, Saux MC et al. Etude pharmacocinetique de la doxycycline chez l'home par chromatographie liquide haute performance. La Nourelle Presse Medicale 1980; 9: 77-81.
25. Dimmling OV. Pharmakokinetik oral and intravenous verabrenchbaver tetracycline prapavate. Med Klin 1975; 70: 279-85.
26. Schreiner A, Digranes A. Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid. Chemotherapy 1985; 31: 261-5.
27. Malmborg A. Bioavailability of doxycycline monocydrate. Chemotherapy 1984; 30: 76-80.
28. Houin G, Brunner F, Nebout T et al. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol 1983; 16: 245-52.
29. Welling PG, Koch PA, Lau CC et al. Bioavailability of tetracycline and doxycycline in fasted and non-fasted subjects. Andmicrob Agents Chemother 1977; 11: 462-9.
30. Campistron G, Coulais Y, Caillard C et al. Pharmacokinetics and bioavailability of doxycycline in humans. Arzneimittelforschung 1986; 36: 1705-7.
31. Wojcicki BJ, Kalinowski W, Gawronska-Szklara B. Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidaemia. Arzneimittelforschung 1985; 35: 991-3.
32. Garraffo R, Dellamonica P, Fournier JP et al. Effet de la rifampicine sur la pharmacocinetique de la doxycycline. Pathologie Biologie 1987; 35: 746-9.
33. Nguyen VX, Nix DE, Gillikin S et al. Effect of oral antacid administration of the pharmacokinetics of intravenous doxycycline. Antimicrob Agents Chemother 1989; 33: 434-6.
34. Heaney D, Eknoyan G. Minocycline and doxycycline kinetics in renal failure. Clin Pharmacol Ther 1978; 24: 233-9.
35. Saux MC, Mosser J, Pontagnier H et al. Pharmacokinetics of doxycycline polyphosphate after oral multiple dosing in humans. Eur J Drug Metab Pharmacokinet 1982; 7: 123-0.
36. Raghuram TC, Krishnaswamy K. Pharmacokinetics and plasma steady state levels of doxycycline in under nutrition. Br J Clin Pharmacol 1982; 14: 785-9.
37. Adadevoh BK, Ogunnaike IA, Bolodeoku JO. Serum levels of doxycycline in normal subjects after a single oral dose. Br Med J 1976; 1: 880.
38. Anonymous. Tetracyclines. In: Kucers A, Crowe SM, Grayson ML, Hoy JF, eds. The Use of Antibiotics. A Clinical Review of Antibacterial Anti-fungal and Anti-viral Drugs, 5th edn. Oxford: Butterworth-Heinemann, 1997; 719-62.
39. Marlin GE, Cheng S, Thompson PJ. Sputum and plasma doxycycline concentrations after a single oral 600 mg doxycycline dose in patients with chronic bronchitis. Eur J Resp Dis 1981; 62:276-80.
40. Gnarpe H, Pornbusch K, Hagg O. Doxycycline concentration levels in bone, soft tissue and serum after intravenous infusion of doxycycline. Scand J Infect Dis Suppl 1976; : 54-7.
41. Alestig K. Studies on doxycycline during intravenous and oral treatment with reference to renal function. Scand J Infect Dis 1973; 5: 193-8.
42. Bocker R, Muhlberg W, Platt D et al. Serum level, half-life and apparent volume of distribution of doxycycline in geriatric patients. Eur J Clin Pharmacol 1986; 30: 105-8.
43. Whelton A, Schach von Wittenau M, Twomey TM et al. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int 1974; 5: 365-71.
44. Klastersky J, Cappell R, Rens B et al. Clinical and bacteriological evaluation of intravenous doxycycline in severe hospital infections. Curr Ther Res Clin Exp 1972; 14: 49-60.
45. Newton PN, Chaulet J-F, Brockman A et al. Pharmacokinetics of oral doxycycline during combination treatment for severe falciparum malaria. Antimicrob Agents Chemother 2005; 49: 1622-5.
46. Anonymous. Minocycline (hydrochloride). In: Dollery C, ed. Therapeutic Drugs, 2nd edn. Churchill-Livingstone, 1999; M187-9.
47. Smith C, Woods CG, Wood MJ. Absorption of minocycline. J Antimicrob Chemother 1984; 13: 93.
48. Wood MJ, Farrell W, Kattan S et al. Activity of minocycline and tetracycline against respiratory pathogens related to blood levels. J Antimicrob Chemother 1975; 1: 323-31.
49. Cartwright AC, Hatfield HL, Yeadon A et al. A comparison of the bioavailability of minocycline capsules and film coated tablets. J Antimicrob Chemother 1975; 1: 317-22.
50. Sklenar I, Spring P, Dettli L. One dose and multiple-dose kinetics of minocycline in patients with renal disease. Agents Action 1977; 7: 369-77.
51. MacDonald H, Kelly RG, Allen ES et al. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1974; 14: 852-61.
52. Carney S, Butcher RA, Dawborn JK et al. Minocycline excretion and distribution in relation to renal function in man. Clin Exp Pharmacol Physiol 1974; 1: 299-308.
53. Welling PG, Shaw WR, Uman SJ et al. Pharmacokinetics of minocycline in renal failure. Antimicrob Agents Chemother 1975; 8:532-7.
54. Nelis HJCF, Leenheer AP. Metabolism of minocycline in humans. Drug metab Dispos 1982; 10: 142-6.
55. Devulder B, Cuvelier D, Tacquet A. Etudes pharmacocinetiques de la minocycline chez des insuffisants renaux chroniques trates ou non par hemodialyse. Lille Med 1974; 19: 287-92.
56. Chaturvedi P, Esposito C, Koroma J et al. In vitro assessment of plasma protein binding and metabolic stability of PTK 0796. In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract F-760, p. 239. American Society for Microbiology, Washington, DC, USA.
57. Cannon EP, White NM, Chaturvedi P et al. Pharmacokinetics of PTK 0796 in mouse, rat and cynomolgus monkey. In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract F-759, p. 238. American Society for Microbiology, Washington, DC, USA.
58. Muralidhavan G, Francillo RJ, Micalizzi M et al. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005; 49: 1656-9.
59. Sun HK, Ong CT, Umer A et al. Pharmacokinetic profile of tigecycline in serum and blister fluid after multiple intravenous administration in healthy adults. In: Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, 2004. Abstract A-12, p. 2-3. American Society for Microbiology, Washington, DC, USA.
60. Meagher AK, Ambrose PG, Grasela TH et al. Pharmacokinetic/ pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent. Diagn Microb Infect Dis 2005; 52: 165-71.
61. Muralidhavan G, Getsy J, Mayer P et al. Pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic in healthy subjects. In: Programs and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 416, p. 303. American Society for Microbiology, Washington, DC, USA.
62. Meagher A, Cirincione B, Piedmonte M et al. Pharmacokinetics of tigecycline in healthy adult volunteers and in subjects with renal impairment. Clin Microbiol Infection 2004; 10 Suppl 3: 1023.
63. Muralidhavan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
64. Rodvold KA, Gotfried MH, Cwik M et al. Tigecycline concentrations in lung tissue, cerebrospinal fluid and bile of human subjects. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-18, p. 4. American Society for Microbiology, Washington, DC, USA.
65. Tombs NL. Tissue distribution of GAR-936, a broad spectrum antibiotic in male rats. In: Programs and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 43, p. 302. American Society for Microbiology, Washington, DC, USA.
66. Hoffman H, Deblaio W, Jordan RA et al. Metabolic disposition of C. tigecycline in human volunteers following intravenous infusion. 2004 AAPS Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Baltimore. http://www.aapspharmaceutica.com (May 2006, date last accessed).
67. Troy SM, Muralidhavan G, Micalizzi M et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-22, p. 5. American Society for Microbiology, Washington, DC, USA.
68. Van Wart S, Cirincione BB, Hirankam S et al. Population pharmacokinetics of tigecycline in phase 1 subjects. In: Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004. Abstract A-10, p. 2. American Society for Microbiology, Washington, DC, USA.
69. Owen JS, Darling IM, Troy SM et al. Noncompartmental pharmacokinetics of tigecycline in patients with complicated skin and skin structure infections. In: Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract A-11, p. 2. American Society for Microbiology, Washington, DC, USA.
70. Darling IM, Cirincione BB, Owen JS. Non-compartmental pharmacokinetics of tigecycline in Phase 3 studies of patients with complicated skin and skin structure and intra abdominal infections. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-20, p. 4-5. American Society for Microbiology, Washington, DC, USA.
71. Zimmerman JJ, Harper D, Matsche K et al. Tigecycline and digoxin co-administered to healthy men. In: Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract A-460, p. 18. American Society for Microbiology, Washington, DC, USA.
72. Raible DG, Zimmerman JJ, Harper DM et al. Pharmacokinetics and pharmacodynamics of tigecycline and warfarin in healthy subjects. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-21, p. 5. American Society for Microbiology, Washington, DC, USA.
73. Craig WA. Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightingale CH, Murakawa T, Ambrose PG, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Oxford: Marcel Dekker, 2002; 1-22.
74. Levison ME. Pharmacodynamics of antimicrobial agents. Bactericidal and post-antibiotic effects. Infect Dis Clin North Am 1995; 9: 483-95.
75. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: A review. Scand J Infect Dis 1999; 74 Suppl: 63-70.
76. Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003; 17: 579-98.
77. Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. Clin Microbiol Infect 2000; 6: 270-3.
78. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22: 1517-23.
79. van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152, 288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 943-9.
80. Murphy TM, Deitz JM, Petersen PJ et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44: 3022-7.
81. Lefort A, Lafaune M, Massias L et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 43: 216-22.
82. Gales AC, Jones RN. Antimicrobial activity and spectrum of a new glycylcycline, GAR 936 tested against 1203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
83. Zhanel GG, Homenvik K, Nochol K et al. The glycylcyclines: A comparative review with the tetracyclines. Drugs 2004; 64: 63-88.
84. Bowker KE, Noel AR, MacGowan AP. Antibacterial effect of minocycline with or without rifampicin on MRSA strains studied in an in vitro pharmacokinetic model. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-443, p. 16. American Society for Microbiology, Washington, DC, USA.
85. Garrison MW, Neumiller JJ. Comparative pharmacodynamic activity of tigecycline against quinolone resistant S. pneumoniae, Methicillin resistant S. aureus and vancomycin resistant Enterococci. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-22, p. 5. American Society for Microbiology, Washington, DC, USA.
86. Rolain J-M, Boulos A, Mallet M-N et al. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q Fever endocarditis. Antimicrob Agents Chemother 2005; 49: 2673-6.
87. Meagher A, Ambrose P, Passarell J et al. A novel approach for evaluating the microbiological efficacy of tigecycline in patients with complicated skin and skin structure infections. Clin Microbiol Infect 2005; 11 Suppl 2: 1183, 373.
88. Meagher A, Passarell J, Cirincione B et al. Exposure-response analysis of the efficacy of tigecycline in patients with complicated skin and skin structure infections. Clin Microbiol Infect 2005; 11 Suppl 2: 1184, 373-4.
89. Meagher AK, Passarell JA, van Wart SA et al. Estimation of in vitro susceptibility breakpoints for tigecycline against Staphylococci. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-1153, p. 22. American Society for Microbiology, Washington, DC, USA.
90. Passarell JA, Liolios K, Meacher AK et al. Exposure response analysis of the efficacy of tigecycline in-patients with complicated intra abdominal infections. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-1155, p. 22. American Society for Microbiology, Washington, DC, USA.
91. Meagher AK, Passarell JA, Liolios K et al. Estimation of in vitro susceptibility breakpoints for the tigecycline against Enterobacteriacae. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract A-1156, p. 22. American Society for Microbiology, Washington, DC, USA.
92. Petersen PJ, Labthavikul P, Jones CH et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill analysis. J Antimicrob Chemother 2006; 57: 573-6.